This is a questionnaire study to establish new ways to measure HS flares. Subjects and providers will each complete questionnaires at regularly occurring visits.

- Medical History and Demographics Review- Weekly Questionnaires- HS Skin Assessments

Up to $320

Phase 1, Double- Blind Study, 15 week study, Patch test and Vaccine Injection, Males/Females 18-65 years old with history of urushiol exposure. The rash or allergic contact dermatitis of poison ivy is recognized as occurring after the exposure to the urushiol oil which is found in the leaves of poison ivy, oak and sumac. Currently there is no preventative treatment for contact dermatitis. The purpose of this study is to find out if the vaccine, PDC-APB can help with the prevention of contact dermatitis.

The purpose of this study is to investigate the use and effectiveness of fatigue and drainage measurement tools for patients with hidradenitis suppurativa (HS). Participants will complete either an interview through Zoom or an online questionnaire.

Participants in this study will either complete an interview through Zoom or an online questionnaire to talk about their experiences with hidradenitis suppurativa fatigue and drainage.

Atopic Dermatitis: Open Label, 64 weeks study. Injectable medicine. Males/Females 2-11 years with moderate to severe atopic dermatitis. The goal of the study is assess the uptake of the drug by the body and safety of nemolizumab administered with topical corticosteroids.

Participants will attend in person visit at the Dermatology Clinical Trial office. Dr. Zaenglein is the pediatric dermatologist in charge of this research study and will do all skin evaluations. In addition at different time points there will be blood that is drawn, questionnaires to be completed, and ECGs will be performed.

Study coordinator will discuss.

Hidradenitis Suppurativa (HS): Assigned to PTM-001 (400mg) or placebo (no active ingredients) for 12 weeks after which all patients will receive the actual study medication, PTM-001 400mg daily for an additional 12 weeks. Males/Females 18 years of age and older.The goal of the study is assess the effect of PTM-001 on skin protein levels.

Atopic Dermatitis (AD): Phase 3 double-blinded study, 8 week study with 44 week long-term safety period with guaranteed study medicine. Topical cream. Male and females ≥ 2 Years to < 12 Years with ADAtopic Dermatitis (AD), also known as eczema, is an inflammatory skin condition that can reoccur repeatedly. AD often causes itching and burning, skin flaking, and red bumps that can crust and open up. The purpose of this study is to find out of the study medicine, ruxolitinib cream, can help with the treatment of AD.

Participants in this research study will need to return to the research site for up to 17 visits over 61 weeks. At this visits, participants will be asked to complete questionnaires, undergo blood draws, complete photography, and undergo physical and skin exams.

Up to $850.00

Patients with the clinical diagnosis of mild, moderate to severe Hidradenditis Suppurativa or normal healthy volunteers ages 18 and older to participate in a 1 time study visit. There is no treatment provided but we may gain information for the treatment of HS.

Eligible participants will attend a one time in person visit. During the visit, the study team will ask you to participate in the following activities: collect skin sample, blood sample and cheek swab. Take photographs of your HS lesions.

study coordinator will discuss.

Phase 1, multiple-dose, open-label study consisting oftwo parts, male and female subjects aged 2 to 12 years with severe atopic dermatitis (eczema).

Studies have show that patients with skin conditions are often subject to social stigma. Exposure to these negative biases can lead to negative feelings for the patient. This study seeks to evaluate how patients with various skin conditions are impacted by these social biases.

Take an online survey that is expected to take 15-20 minutes. You will be asked to provide your email and take a short (5-10 minute) survey with some of the same questions 72 hours later.

Hidradenitis Suppurativa: Phase 2 Subject and Investigator Blinded, 7 and a half month study. Platform Study: Injectable and Oral drug, Males/Females 18-65 years old with Hidradenitis Suppurativa. Hidradenitis Suppurativa (HS) is a chronic recurrent and debilitating skin condition that typically presents with deep and painful lesions. The most common areas affected are the armpits, the groin, and the anus and genitals area. The purpose of the study is to find out if the study drugs (iscalimab and LYS006) are beneficial and safe in patients with HS.

For this study there are up to 11 visits over a period of 6 months. Subjects will take an oral medication twice a day for 16 weeks and will come to the study site for questionnaires, physical exams, EKGs, blood draws, and urine testing at multiple visits.

Up to $500.00

Moderate to Severe Acne Vulgaris: Males/Females 16 years and older. You will receive the study drug with either 1 hour or 3 hours between study drug application and illumination. The purpose of this study is to test the effectiveness and safety of the study drug, used at two different incubation times (time starting with administration of study drug until start of the red light illumination).

Subjects will attend in person visits in the Dermatology Clinical Trial Office. Your length of participation will depend on how your acne responds to the first treatment; the length of participation for 3 treatments will be approximately 25 weeks.Throughout the study at different time points Dr. Zaenglein will evaluate your acne, blood will be drawn, photos will be taken, and questionnaires will need to be completed.

Study Coordinator will discuss during phone screen.

Mild to Severe Acne: Women ages 16-40 years. Assigned to either spironolactone of doxycycline; oral medication taken once daily. The duration of the study will last 16 weeks. During that time participants will attend 3 in person study visits (study start, week 8 and week 16). In addition participants will completion questions outside of study visits at Week 4 and Week 12. The goal of this trial is to compare the effectiveness of spironolactone and doxycycline hyclate in the treatment of acne in women.

The duration of the study will last 16 weeks. During that time participants will attend 3 in person study visits (study start, week 8 and week 16). In addition participants will completion questions outside of study visits at Week 4 and Week 12.

This study is aiming to identify the differences in medicated hair care practices amongst adult patients with scalp conditions. Typical treatment for scalp conditions involves the continued use of medicated shampoos; however, hair care practices across all ethnic and racial barriers are different. This could impact the effectiveness of these medicated washes if they are by chance not being used frequently enough. To our knowledge, no research has explored hair care practices and their relationship to dermatological conditions that affect the scalp.

Participants will complete a one-time survey that will take approximately 5-10 minutes.

SLE/CLE Lupus: 18 years and older; SC (subcutaneous injection) every 4 weeks with an additional dose given at Week 2 and Week 26. Randomization is 2:1 BIIB059 to placebo (non active ingredient); 52 weeks of treatment. There are 2 parts to the study, Part A and Part B. The goal of Part A is to confirm the adequacy of an investigator specific evaluation. The goal of Part B is to demonstrate the efficacy and safety of BIIB059 compared with placebo.

You will attend 21 visits and have 2 phone calls over approximately 52 weeks. At different time points throughout the study you will have photographs taken of your lesions, labs drawn, an ECG performed, skin examinations, a chest x-ray, you will need to complete questions, and fill out a diary.

This survey study is looking to see how post-inflammatory hyperpigmentation (PIH) affects quality of life in people with skin of color.

Participants will complete a one-time survey that will ask about post-inflammatory hyperpigmentation.

The purpose of this research study is to collect skin samples from volunteers with HS and volunteers with healthy skin. The collected skin samples will be processed and compared to each other to see if there are specific differences in the skin between the HS volunteer group and the healthy skin volunteer group.

Participants will need to come to a one-time, in-person visit where biopsies (small skin samples) will be collected.- For participants with HS: Up to 4 biopsies will be collected - For participants with healthy skin: Up to 2 biopsies will be collected

Site For AbbVie- HS Surgery

Explore all stages of Hidradenitis Suppurativa with a topical medication.

There will be 7 in-person visits and 1 follow-up phone call over a 33 week period. Over the course of the study, the following study procedures will take place: medical history and medication history collection, ECG, lab tests (both blood and urine), photography, skin exams, physical exams, questionnaires, and skin biopsies.

Up to $350

The aim of this study is to obtain information regarding the incidence of hair-related concerns in women who wear hijab and to collect information pertaining to factors that could contribute to hair loss in women who wear the hijab.

This survey study will involve a one-time survey that will take 5-10 minutes.